PriceTargets.com logo

Pharnext - PNEXF Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$400.00 As of 07/13/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for PNEXF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pharnext Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PNEXF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PNEXF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Pharnext in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $400.00.

This chart shows the closing price for PNEXF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Pharnext. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/15/2021Kepler Capital MarketsReiterated RatingBuy$5,000,000,000,000,000.00
6/10/2021CheuvreuxUpgradeHold ➝ Buy
10/18/2020Kepler Capital MarketsReiterated RatingHold ➝ Neutral
4/24/2020Kepler Capital MarketsDowngradeHold
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

Pharnext

Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.
Read More

Today's Range

Now: $400.00
Low: $400.00
High: $400.00

50 Day Range

MA: $400.00
Low: $400.00
High: $400.00

52 Week Range

Now: $400.00
Low: $0.00
High: $0.00

Volume

16,660 shs

Average Volume

433 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pharnext?

The following Wall Street research analysts have issued reports on Pharnext in the last year:
View the latest analyst ratings for PNEXF.

What is the current price target for Pharnext?

0 Wall Street analysts have set twelve-month price targets for Pharnext in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pharnext in the next year.
View the latest price targets for PNEXF.

What is the current consensus analyst rating for Pharnext?

Pharnext currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PNEXF.

What other companies compete with Pharnext?

Other companies that are similar to Pharnext include 180 Life Sciences, 3SBio, 60 Degrees Pharmaceuticals, Abcam and Adocia. Learn More about companies similar to Pharnext.

How do I contact Pharnext's investor relations team?

Pharnext's physical mailing address is 46 rue Saint Lazare, Paris, Ile-de-France 75009. The company's listed phone number is (314) 109-2230. The official website for Pharnext is www.pharnext.com. Learn More about contacing Pharnext investor relations.